秋水仙碱在心血管疾病中的应用
综述总结秋水仙碱在心血管疾病中的疗效与安全性。超过1600例心包炎患者的试验显示秋水仙碱使复发风险减半(RR 0.50,95%CI 0.42-0.60);每日0.5-1.0 mg剂量在心血管试验中安全,约10%患者因早期胃肠道不耐受受限,约90%长期耐受良好。
要点
- 秋水仙碱使急性和复发性心包炎复发风险减半(RR 0.50)。
- 急性或慢性冠脉综合征患者中,秋水仙碱可能降低缺血事件风险超过30%。
- 每日0.5-1.0 mg剂量安全,约90%患者长期耐受良好。
核心结论
- 秋水仙碱在急性和复发性心包炎及急性或慢性冠脉综合征患者中显示出降低事件风险的疗效,且每日0.5-1.0 mg剂量安全性良好。
研究设计与样本
- 本文为综述,汇总了秋水仙碱在心血管疾病中的当代数据。
- 心包炎临床试验纳入超过1600例患者。
主要发现
- 在急性和复发性心包炎患者中,秋水仙碱使复发风险减半(RR 0.50,95%CI 0.42-0.60)。
- 在急性或慢性冠脉综合征患者中,秋水仙碱可能降低心血管死亡、心肌梗死、缺血性卒中及缺血驱动的血运重建风险超过30%(RR 0.63,95%CI 0.49-0.81)。
- 每日0.5-1.0 mg秋水仙碱在心血管试验中安全;约10%患者因早期胃肠道不耐受限制使用,约90%长期耐受良好。
- 在无晚期肾或肝病且使用上述剂量时,与中度至强CYP3A4抑制剂/竞争剂或P-糖蛋白抑制剂/竞争剂的临床相关药物相互作用罕见。
关键数值与推荐
- 心包炎患者复发风险:RR 0.50(95%CI 0.42-0.60)。
- 冠脉综合征患者缺血事件风险:RR 0.63(95%CI 0.49-0.81)。
- 心血管试验中秋水仙碱剂量:每日0.5-1.0 mg。
临床怎么用
- 对于急性和复发性心包炎患者,可考虑使用秋水仙碱以降低复发风险。
- 对于急性或慢性冠脉综合征患者,可考虑使用秋水仙碱以降低缺血事件风险。
- 使用每日0.5-1.0 mg剂量时需注意胃肠道不耐受,并评估肾和肝功能及药物相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colchicine is a unique, sophisticated anti-inflammatory agent that has been used for decades for the prevention of acute inflammatory flares in gout and familial Mediterranean fever. In recent years, clinical trials have demonstrated its potential in a range of cardiovascular (CV) conditions. Colchicine is avidly taken up by leucocytes, and its ability to bind to tubulin and interfere with microtubular function affects the expression of cytokines and interleukins, and the ability of neutrophils to marginate, ingress, aggregate, express superoxide, release neutrophil extracellular traps, and interact with platelets. In patients with acute and recurrent pericarditis, clinical trials in >1600 patients have consistently shown that colchicine halves the risk of recurrence [relative risk (RR) 0.50, 95% confidence interval (CI) 0.42-0.60]. In patients with acute and chronic coronary syndromes, multicentre randomized controlled trials in >11 000 patients followed for up to 5 years demonstrated that colchicine may reduce the risk of CV death, myocardial infarction, ischaemic stroke and ischaemia-driven revascularization by >30% (RR 0.63, 95% CI 0.49-0.81). The use of colchicine at doses of 0.5-1.0 mg daily in CV trials has proved safe. Early gastrointestinal intolerance limits its use in ∼10% of patients; however, ∼90% of patients tolerate it well over the long term. Despite isolated case reports, clinically relevant drug interactions with moderate to strong CYP3A4 inhibitors/competitors or P-glycoprotein inhibitors/competitors are rare if this dosage of colchicine is used in the absence of advanced renal or liver disease. The aim of this review is to summarize the contemporary data supporting the efficacy and safety of colchicine in patients with CV disease.
引用
- Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021. PMID: 33961006. doi:10.1093/eurheartj/ehab221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。